Familial Hyperlysinemia with Lysine-Ketoglutarate Reductase Insufficiency

Total Page:16

File Type:pdf, Size:1020Kb

Familial Hyperlysinemia with Lysine-Ketoglutarate Reductase Insufficiency Familial hyperlysinemia with lysine-ketoglutarate reductase insufficiency Joseph Dancis, … , Rody P. Cox, Norman C. Woody J Clin Invest. 1969;48(8):1447-1452. https://doi.org/10.1172/JCI106110. Research Article Fibroblasts grown in tissue culture from the skin of normal subjects have lysine-ketoglutarate reductase activity (lysine: α- ketoglutarate: triphosphopyridine nucleotide (TPNH) oxidoreductase (ε-N-[L-glutaryl-2]-L-lysine forming)). The activity of the enzyme is considerably reduced in the skin fibroblasts grown from three siblings with hyperlysinemia. The high concentrations of lysine in the blood of these patients, the previous demonstration in the intact subject of a reduction in the ability to degrade lysine, and the present demonstration of diminished lysine-ketoglutarate reductase activity, accurately define the metabolic defect and establish the saccharopine (ε-N-[L-glutaryl-2]-L-lysine) pathway as the major degradative pathway for lysine in the human. Find the latest version: https://jci.me/106110/pdf Familial Hyperlysinemia with Lysine- Ketoglutarate Reductase Insufficiency JOSEPH DANCGS, JOEL HurziER, RODY P. Cox, and NORMAN C. WOODY From the Departments of Pediatrics and Medicine, New York University School of Medicine, New York 10016, and the Department of Pediatrics, Tulane Medical School, New Orleans, Louisiana 70112 A B S T R A C T Fibroblasts grown in tissue culture from made it possible to investigate more specifically the en- the skin of normal subjects have lysine-ketoglutarate zyme defect. In the present study, it has been demon- reductase activity (lysine: a-ketoglutarate: triphospho- strated that fibroblasts grown in tissue culture from skin pyridine nucleotide (TPNH) oxidoreductase (c-N- [L- biopsies obtained from normal subjects convert lysine to glutaryl-2] -L-lysine forming)). The activity of the en- saccharopine. In comparison, the lysine-ketoglutarate zyme is considerably reduced in the skin fibroblasts reductase activity was considerably reduced in the skin grown from three siblings with hyperlysinemia. The fibroblasts of the three siblings with the disease. The re- high concentrations of lysine in the blood of these pa- sults accurately define the enzyme defect in the disease tients, the previous demonstration in the intact subject and establish the saccharopine pathway as the major of a reduction in the ability to degrade lysine, and the degradative pathway for lysine. present demonstration of diminished lysine-ketoglutarate reductase activity, accurately define the metabolic defect METHODS and establish the saccharopine (c-N- [L-glutaryl-2] -L- Materials lysine) pathway as the major degradative pathway for lysine in the human. L-lysine-U-14C was purchased from New England Nuclear Corp., Boston, Mass. A trace radioactive contaminant with electrophoretic properties similar to saccharopine was re- INTRODUCTION moved by passage through a column of Rexyn 206 (OH-), Fisher Scientific Company, New York. The resin was pre- In 1964, a 4J yr old girl was reported with mental retar- pared by cycling with 3 N HCl and 1 N ammonium hydrox- dation, excessive lysinuria, and hyperlysinemia (1). ide and then was left in the hydroxyl phase. Under these Since then two additional siblings and a first cousin have conditions, lysine was eluted from the column with water. been discovered to have a similar metabolic abnormality. Cab-O-Sil, fumed silica, grade M5, was obtained from Cabot Corporation, Boston, Mass. Saccharopine was ex- The metabolism of lysine has been studied in vivo in two tracted from yeast by methods previously described (5). of the siblings and evidence has been presented that a defect exists in the degradative pathway for lysine prob- Tissue culture ably at the first metabolic step (2). Skin biopsies were obtained from the three patients with The recent demonstration of saccharopine (E-N-[L- hyperlysinemia and grown in monolayer in Waymouth's glutaryl-2]-L-lysine) formation from lysine in the rat medium containing 10%o calf serum and antibiotics (peni- (3, 4) and in the human (5), and the development in cillin 50 U/ml, streptomycin, 50 /Ag/ml, and kanamycin 30 this laboratory of a microassay for the responsible en- ,Ag/ml). Foreskins obtained at circumcision of newborn infants were cultured as normal controls. Subcultures of the zyme, lysine-ketoglutarate reductase, (lysine: a-ketoglu- explants were permitted to grow to confluence in 4-oz glass tarate: triphosphopyridine nucleotide (TPNH) oxido- bottles. At the time of assay, the normal cells had pro- reductase (E-N-[L-glutaryl-2]-L-lysine forming)) have liferated for 10-18 generations and the hyperlysinemics for 16-20 generations. Dr. Dancis is Career Investigator, the National Institute of Child Health and Human Development. Dr. Cox is Enzyme assay Career Scientist, Health Research Council of the City of New York. The fibroblasts from four bottles, representing a total of Received for publication 17 January 1969 and in revised approximately 4 million cells, were harvested by replacing form 3 April 1969. the nutrient medium with 5 ml of a 15: 85 v/v mixture of The Journal of Clinical Investigation Volume 48 1969 1447 300F- CONTROL G.G. PATIENT Al Orbigin Origin 2001 - A _I B V A B CONTROL M.M. PATIENT 11 z 0LS 2001 cLJ tn 100 z _m1m B m B 0 (.. L - CONTROL SS. PATIENT R.I. A - A / m B SCAN DIRECTION- FIGURE 1 Radioactive pattern after high-voltage electrophoresis of incubation media. Disrupted skin fibroblasts were incubated with lysine-14C. The incubation medium was applied to paper and subjected to high-voltage electrophoresis. Lysine migrates towards the cathode, and has been omitted from the radioactive scan. The control fibroblasts produce a radioactive peak corresponding in mobility to an internal standard of sac- charopine (stippled bar), not evident after incubation with fibroblasts from hyperlysinemic subjects. sodium phosphate, 0.11 mole/liter, pH 7.4, and 0.15 M NaCl, pH 6.7. A lower pH was used than that previously reported and removing the cells from the bottle with a rubber (5) to better separate an unidentified radioactive peak (see policeman. The suspension was centrifuged at 2000 g for 15 Fig. 1, peak A) from saccharopine. The strip was surveyed min, and the supernatant discarded. The cells were stored in a Nuclear-Chicago Actigraph III strip counter. The at -15'C for 4 days or more before testing. saccharopine peak was located by removing a 2 mm wide For assay, the cells were thawed in a 230C water bath strip from the paper and developing with ninhydrin. The and 0.15 ml of 0.05 M KC1 was added. The fibroblasts were remainder of the saccharopine area was removed, cut into then disrupted by cycling five times between a dry-ice bath small pieces with scissors, and eluted by shaking for 15 mmi and the water bath over a period of 30 min, aided by occa- in 5 ml of water at 60'C. The process was repeated and sional stirring with a glass rod. To each sample of disrupted the eluates pooled, filtered, and evaporated to dryness under cells was added the following incubation mixture: L-lysine- vacuum. The residue was dissolved in 1 ml of citrate U-14C, 0.5 juc, 1.0 umole; MgCl2, 0.05 /moles; potassium buffer, pH 2.8.1 a-ketoglutarate, 2 etmoles; potassium phosphate, pH 7.1, 10 Column chromatography. Approximately 0.2 jtmoles of /Amoles; TPNH, 1.5 Amoles; and water to a final volume methionine was added to the sample as a marker and the of 0.5 ml. Incubation was with agitation for 60 min at mixture applied to a Phoenix Micro Analyzer with a 0.9 30'C under a stream of nitrogen. X 15 cm column containing Spherix resin XX907-10-OPKU. To terminate the incubation, 5 tmoles of saccharopine in Elution was with 0.2 M sodium citrate buffer, pH 3.25,1 and 0.05 ml water was added to the incubation mixture and the a flow rate of 1 ml/min. The saccharopine peak appeared reaction tubes were placed in a boiling water bath for at 63 min. 5 min. The tubes were centrifuged while hot, and the super- Determination of radioactivity. The saccharopine peak natant removed for analysis. The amount of protein in the was collected at the outflow of the colorimeter into scintil- precipitate was measured by dissolving the precipitate in 1.0 lation counting vials in 1-min aliquots. The ninhydrin color N NaOH and assaying the protein content by the method was bleached by the addition of 0.1 ml 30%o hydrogen per- of Lowry (6). This provided an indication of the number oxide to each vial, and the contents evaporated to dryness of cells incubated. in a water bath at 600C. The residue was dissolved in 0.5 ml water. To this was added 11 ml methanol, approximately Analysis 270 mg Cab-O-Sil (to produce a gel), and 9 ml of the scintillant mixture containing (per liter) : 2,5-diphenyloxazole High voltage electrophoresis. 0.1 ml of the incubation medium was applied to Whatman 3MM paper and subjected The composition was that described by Hamilton (7) to 2000 v for 3 hr in 0.05 M potassium phosphate buffer, for buffer, pH 2.875, with the pH corrected by titration. 1448 J. Dancis, J. Hutzler, R. P. Cox, and N. C. Woody PATIENT Ii. 0.5 C)~~~~~~~~~~~~~~~ at' ~~~~~~~~~~~~~C 0~~~~~~~~~~~~~~~~~~~~0 = 2 2002 0 ~~~~~~~~~~~~~~~~~00 75 65 55 45 75 65 55 45 Minutes FIGuRE 2 Column chromatography of presumed saccharopine. After high-voltage electrophoresis (Fig. 1), the saccharopine area was eluted and analyzed by column chromatography. The ninhydrin optical density (continuous line) is indicated by the left ordinate; radioactivity by the bar graph and the right ordinate. Methionine was added as an internal standard and appears to the left of the sac- charopine peak.
Recommended publications
  • Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis
    Pediat. Res. 10: 683- 686 (1976) Fatty degeneration propionic acid hyperammonemia propionic acidemia liver ureagenesls Effect of Propionic Acid on Fatty Acid Oxidation and U reagenesis ALLEN M. GLASGOW(23) AND H. PET ER C HASE UniversilY of Colorado Medical Celller, B. F. SlOlillsky LaboralOries , Denver, Colorado, USA Extract phosphate-buffered salin e, harvested with a brief treatment wi th tryps in- EDTA, washed twice with ph os ph ate-buffered saline, and Propionic acid significantly inhibited "CO z production from then suspended in ph os ph ate-buffe red saline (145 m M N a, 4.15 [I-"ejpalmitate at a concentration of 10 11 M in control fibroblasts m M K, 140 m M c/, 9.36 m M PO" pH 7.4) . I n mos t cases the cells and 100 11M in methyl malonic fibroblasts. This inhibition was we re incubated in 3 ml phosph ate-bu ffered sa lin e cont aining 0.5 similar to that produced by 4-pentenoic acid. Methylmalonic acid I1Ci ll-I4Cj palm it ate (19), final concentration approximately 3 11M also inhibited ' 'C0 2 production from [V 'ejpalmitate, but only at a added in 10 II I hexane. Increasing the amount of hexane to 100 II I concentration of I mM in control cells and 5 mM in methyl malonic did not impair palmit ate ox id ation. In two experiments (Fig. 3) the cells. fibroblasts were in cub ated in 3 ml calcium-free Krebs-Ringer Propionic acid (5 mM) also inhibited ureagenesis in rat liver phosphate buffer (2) co nt ain in g 5 g/ 100 ml essent iall y fatty ac id slices when ammonia was the substrate but not with aspartate and free bovine se rum albumin (20), I mM pa lm itate, and the same citrulline as substrates.
    [Show full text]
  • Inherited Metabolic Disease
    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
    [Show full text]
  • Metabolomic Analysis Reveals That the Drosophila Gene Lysine Influences Diverse Aspects of Metabolism
    Genetics: Early Online, published on October 6, 2017 as 10.1534/genetics.117.300201 Metabolomic analysis reveals that the Drosophila gene lysine influences diverse aspects of metabolism Samantha L. St. Clair*‡, Hongde Li*‡, Usman Ashraf†, Jonathan A. Karty†, and Jason M. *§ Tennessen * Department of Biology, Indiana University, Bloomington, IN 47405, USA † Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA. ‡ These authors contributed equally to this work. § Correspondence: [email protected] Keywords: Drosophila, metabolomics, lysine, LKRSDH, familial hyperlysinemia 1 Copyright 2017. ABSTRACT The fruit fly Drosophila melanogaster has emerged as a powerful model for investigating the molecular mechanisms that regulate animal metabolism. A major limitation of these studies, however, is that many metabolic assays are tedious, dedicated to analyzing a single molecule, and rely on indirect measurements. As a result, Drosophila geneticists commonly use candidate gene approaches, which, while important, bias studies towards known metabolic regulators. In an effort to expand the scope of Drosophila metabolic studies, we used the classic mutant lysine (lys) to demonstrate how a modern metabolomics approach can be used to conduct forward genetic studies. Using an inexpensive and well-established gas chromatography-mass spectrometry (GC-MS)-based method, we genetically mapped and molecularly characterized lys by using free lysine levels as a phenotypic readout. Our efforts revealed that lys encodes the Drosophila homolog of Lysine Ketoglutarate Reductase/Saccharopine Dehydrogenase (LKRSDH), which is required for the enzymatic degradation of lysine. Furthermore, this approach also allowed us to simultaneously survey a large swath of intermediate metabolism, thus demonstrating that Drosophila lysine catabolism is complex and capable of influencing seemingly unrelated metabolic pathways.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Table S1. Disease Classification and Disease-Reaction Association
    Table S1. Disease classification and disease-reaction association Disorder class Associated reactions cross Disease Ref[Goh check et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0134109 A1 Gaitanaris Et Al
    US 2006O134109A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0134109 A1 Gaitanaris et al. (43) Pub. Date: Jun. 22, 2006 (54) GPROTEIN COUPLED RECEPTORS AND in-part of application No. 60/461.329, filed on Apr. 9. USES THEREOF 2003. (75) Inventors: George A. Gaitanaris, Seattle, WA Publication Classification (US); John E. Bergmann, Mercer Island, WA (US); Alexander Gragerov, (51) Int. Cl. Seattle, WA (US); John Hohmann, La CI2O I/68 (2006.01) Conner, WA (US); Fusheng Li, Seattle, C7H 2L/04 (2006.01) WA (US); Linda Madisen, Seattle, WA (US); Kellie L. McIlwain, Renton, WA CI2P 2/06 (2006.01) (US); Maria N. Pavlova, Seattle, WA A 6LX 39/395 (2006.01) (US); Demitri Vassilatis, Seattle, WA C07K I4/705 (2006.01) (US); Hongkui Zeng, Shoreline, WA (52) U.S. Cl. ......................... 424/143.1: 435/6: 435/69.1; 435/320.1; 435/325; 530/350; (US) 536/23.5 Correspondence Address: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC (57) ABSTRACT 701 FIFTHAVE SUTE 63OO The present invention provides GPCR polypeptides and SEATTLE, WA 98104-7092 (US) polynucleotides, recombinant materials, and transgenic (73) Assignee: Nura Inc., Seattle, WA (US) mice, as well as methods for their production. The polypep tides and polynucleotides are useful, for example, in meth (21) Appl. No.: 10/527,265 ods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying com (22) PCT Fed: Sep. 9, 2003 pounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for (86) PCT No.: PCT/USO3/28226 treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified com Related U.S.
    [Show full text]
  • 23 Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism
    23 Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism Georg F. Hoffmann 23.1 Introduction – 295 23.2 Hyperlysinemia/Saccharopinuria – 295 23.2.1 Clinical Presentation – 295 23.2.2 Metabolic Derangement – 295 23.2.3 Genetics – 296 23.2.4 Diagnostic Tests – 296 23.2.5 Treatment and Prognosis – 296 23.3 Hydroxylysinuria – 296 23.4 2-Amino-/2-Oxo-Adipic Aciduria – 296 23.4.1 Clinical Presentation – 296 23.4.2 Metabolic Derangement – 296 23.4.3 Genetics – 296 23.4.4 Diagnostic Tests – 296 23.4.5 Treatment and Prognosis – 297 23.5 Glutaric Aciduria Type I (Glutaryl-CoA Dehydrogenase Deficiency) – 297 23.5.1 Clinical Presentation – 297 23.5.2 Metabolic Derangement – 297 23.5.3 Genetics – 300 23.5.4 Diagnostic Tests – 300 23.5.5 Treatment and Prognosis – 301 23.6 L-2-Hydroxyglutaric Aciduria – 302 23.6.1 Clinical Presentation – 302 23.6.2 Metabolic Derangement – 303 23.6.3 Genetics – 303 23.6.4 Diagnostic Tests – 303 23.6.5 Treatment and Prognosis – 303 23.7 D-2-Hydroxyglutaric Aciduria – 303 23.7.1 Clinical Presentation – 303 23.7.2 Metabolic Derangement – 303 23.7.3 Genetics – 303 23.7.4 Diagnostic Tests – 304 23.7.5 Treatment and Prognosis – 304 23.8 N-Acetylaspartic Aciduria (Canavan Disease) – 304 23.8.1 Clinical Presentation – 304 23.8.2 Metabolic Derangement – 304 23.8.3 Genetics – 304 23.8.4 Diagnostic Tests – 304 23.8.5 Treatment and Prognosis – 305 References – 305 294 Chapter 23 · Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism Catabolism of Lysine, Hydroxylysine, and Tryptophan Lysine, hydroxylysine and tryptophan are degraded with- otide (FAD) and hence to the respiratory chain (.
    [Show full text]
  • Intestinal Phosphate Transport in Familial ~~~O~Hos~Haternicrickets
    FAMILIAL HYPOPHOSPHATEMIC RICKETS 69 1 pine oxidoreductase. The deficiencies were confirmed in skin Glutaric aciduria: A "new" disorder of amino acid metabolism. Biochem. fibroblasts from two siblings with the disease and a third patient Med., 12: 12 (1975). 15. Hutzler, J., and Dancis. J.: Saccharopine cleavage by a dehydrogenase of human from an unrelated family. liver. Biochim. Biophys. Acta. 206: 205 (1970). REFERENCES AND NOTES 16. Hutzler. J., and Dancis. J.: Preparative synthesis of saccharopine. Biochim. Biophys. Acta, 222: 225 (1970). I. Ampola. M. G., Ampola. M., Mian, M., Shaw, W., Levy, H., Letsou, A,, and 17. Hutzler, J., and Dancis, J.: Lysine-ketoglutarate reductase in human tissues. Doyle. M.: In preparation. Biochim. Biophys. Acta, 377: 42 (1975). 2. Bowden, J. A., and Connelly, J. L.: Branched-chain a-keto acid metabolism. I. 18. Krooth, R. S.: Constitutive mutations and hereditary enzyme deficiencies in Isolation, purification and partial characterization of bovine liver a- mammalian cells. In: M. Harris and B. Thompson: Regulation of Gene ketoisocaproic:a-keto-@-methylvaleric acid dehydrogenase. J. Biol. Chem., Expression in Eukaryotic Cells, p. 115 (Fogarty International Center, Be- 243: 1 198 (1968). thesda, Md., 1973). 3. Cox. R. P.. Krauss, M. R., Balis, M. E., and Dancis, J.: Communication between 19. Lormans, S., and Lowenthal. A,: Amino adipic aciduria in an oligophrenic child. normal and enzyme deficient cells in tissue culture. Exp. Cell Res.. 74: 251 Clin. Chim. Acta. 57: 97 (1974). (1972). 20. Lowry. 0. H., Rosehrough, N. J.. Farr. A. L., and Randall, R. J.: Protein 4. Cox. R. P., and MacLeod, C.
    [Show full text]
  • Attachment a Rare and Expensive Disease List As of December 27, 2010 ICD-9 Age Disease Guidelines Code Group 042
    Attachment A Rare and Expensive Disease List as of December 27, 2010 ICD-9 Age Disease Guidelines Code Group 042. Symptomatic HIV disease/AIDS 0-20 (A) A child <18 mos. who is known to be HIV (pediatric) seropositive or born to an HIV-infected mother and: * Has positive results on two separate specimens (excluding cord blood) from any of the following HIV detection tests: --HIV culture (2 separate cultures) --HIV polymerase chain reaction (PCR) --HIV antigen (p24) N.B. Repeated testing in first 6 mos. of life; optimal timing is age 1 month and age 4-6 mos. or * Meets criteria for Acquired Immunodeficiency Syndrome (AIDS) diagnosis based on the 1987 AIDS surveillance case definition V08 Asymptomatic HIV status 0-20 (B) A child >18 mos. born to an HIV-infected (pediatric) mother or any child infected by blood, blood products, or other known modes of transmission (e.g., sexual contact) who: * Is HIV-antibody positive by confirmatory Western blot or immunofluorescense assay (IFA) or * Meets any of the criteria in (A) above 795.71 Infant with inconclusive HIV result 0-12 (E) A child who does not meet the criteria above months who: * Is HIV seropositive by ELISA and confirmatory Western blot or IFA and is 18 mos. or less in age at the time of the test or * Has unknown antibody status, but was born to a mother known to be infected with HIV 270.0 Disturbances of amino-acid 0-20 Clinical history and physical exam; laboratory transport studies supporting diagnosis. Subspecialist Cystinosis consultation note may be required.
    [Show full text]
  • Diseases Catalogue
    Diseases catalogue AA Disorders of amino acid metabolism OMIM Group of disorders affecting genes that codify proteins involved in the catabolism of amino acids or in the functional maintenance of the different coenzymes. AA Alkaptonuria: homogentisate dioxygenase deficiency 203500 AA Phenylketonuria: phenylalanine hydroxylase (PAH) 261600 AA Defects of tetrahydrobiopterine (BH 4) metabolism: AA 6-Piruvoyl-tetrahydropterin synthase deficiency (PTS) 261640 AA Dihydropteridine reductase deficiency (DHPR) 261630 AA Pterin-carbinolamine dehydratase 126090 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal recessive) 233910 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal dominant): Segawa syndrome 600225 AA Sepiapterin reductase deficiency (SPR) 182125 AA Defects of sulfur amino acid metabolism: AA N(5,10)-methylene-tetrahydrofolate reductase deficiency (MTHFR) 236250 AA Homocystinuria due to cystathionine beta-synthase deficiency (CBS) 236200 AA Methionine adenosyltransferase deficiency 250850 AA Methionine synthase deficiency (MTR, cblG) 250940 AA Methionine synthase reductase deficiency; (MTRR, CblE) 236270 AA Sulfite oxidase deficiency 272300 AA Molybdenum cofactor deficiency: combined deficiency of sulfite oxidase and xanthine oxidase 252150 AA S-adenosylhomocysteine hydrolase deficiency 180960 AA Cystathioninuria 219500 AA Hyperhomocysteinemia 603174 AA Defects of gamma-glutathione cycle: glutathione synthetase deficiency (5-oxo-prolinuria) 266130 AA Defects of histidine metabolism: Histidinemia 235800 AA Defects of lysine and
    [Show full text]
  • Familial Hyperlysinemia
    Familial Hyperlysinemia Familial hyperlysinemia is an inborn error of metabolism v. Dominant and recessive forms of inherited sub- caused by a defect in the bifunctional protein α-aminoadipic luxation of the lens semialdehyde synthase. DIAGNOSTIC INVESTIGATIONS GENETICS/BASIC DEFECTS 1. Plasma amino acid quantitative analysis: hyperlysinemia 1. Inheritance: autosomal recessive 2. Urinary amino acid quantitative analysis: hyperlysinuria 2. A heterogeneous group of at least three disorders 3. Urinary organic acid analysis: variable saccharopinuria a. Caused by mutations in the gene encoding α-aminoad- 4. Cultured skin fibroblasts: absent lysine-ketoglutarate ipic semialdehyde synthase (AASS), the bifunctional reductase and saccharopine dehydrogenase activities protein that contains both lysine-ketoglutarate reduc- 5. Molecular genetic study: homozygous deletion in AASS tase (LKR) and saccharopine dehydrogenase (SDH) gene activity 6. EEG for seizures b. Deficiency in lysine-ketoglutarate reductase (LKR) and/or saccharopine dehydrogenase (SDH) activities GENETIC COUNSELING leads to a clinical phenotype characterized by hyper- 1. Recurrence risk lysinemia, lysinuria and variable saccharopinuria a. Patient’s sib: 25% c. Deficiency in saccharopine oxidoreductase activity, b. Patient’s offspring: not increased unless the spouse is along with deficient LKR and SDH activities, is also a carrier in which case 50% of the offspring will be observed in children with familial hyperlysinemia. affected 2. Prenatal diagnosis has not been reported CLINICAL FEATURES 3. Management a. Dietary control with reduction in lysine intake 1. Mental retardation of varying degree b. Other supportive therapies 2. Other neurolomuscular manifestations a. Poor muscle tone (hypotonia) b. Muscle weakness REFERENCES c. Clumsy hand movements Armstrong MD, Robinow M: A case of hyperlysinemia: biochemical and clin- d.
    [Show full text]
  • Sudden Unexpected Fatal Encephalopathy in Adults with OTC
    Cavicchi et al. Orphanet Journal of Rare Diseases 2014, 9:105 http://www.ojrd.com/content/9/1/105 RESEARCH Open Access Sudden unexpected fatal encephalopathy in adults with OTC gene mutations-Clues for early diagnosis and timely treatment Catia Cavicchi1, Maria Alice Donati2,RossellaParini3, Miriam Rigoldi3, Mauro Bernardi4, Francesca Orfei5, Nicolò Gentiloni Silveri6, Aniello Colasante7,SilviaFunghini8, Serena Catarzi1, Elisabetta Pasquini2, Giancarlo la Marca8,9, Sean David Mooney10, Renzo Guerrini9,11 and Amelia Morrone1,9* Abstract Background: X-linked Ornithine Transcarbamylase deficiency (OTCD) is often unrecognized in adults, as clinical manifestations are non-specific, often episodic and unmasked by precipitants, and laboratory findings can be normal outside the acute phase. It may thus be associated with significant mortality if not promptly recognized and treated. The aim of this study was to provide clues for recognition of OTCD in adults and analyze the environmental factors that, interacting with OTC gene mutations, might have triggered acute clinical manifestations. Methods: We carried out a clinical, biochemical and molecular study on five unrelated adult patients (one female and four males) with late onset OTCD, who presented to the Emergency Department (ED) with initial fatal encephalopathy. The molecular study consisted of OTC gene sequencing in the probands and family members and in silico characterization of the newly detected mutations. Results: We identified two new, c.119G>T (p.Arg40Leu) and c.314G>A (p.Gly105Glu), and three known OTC mutations. Both new mutations were predicted to cause a structural destabilization, correlating with late onset OTCD. We also identified, among the family members, 8 heterozygous females and 2 hemizygous asymptomatic males.
    [Show full text]